Background: In chronic obstructive pulmonary disease (COPD), low muscle mass has been associated with several clinical outcomes such as low exercise capacity, hospital admission, and mortality. The Sarcopenia Index (SI) is a novel way to estimate muscle mass based on the ratio of serum creatinine (produced exclusively by muscle)/cystatin C (produced by all nucleated body cells). Objectives: This study aims to assess the SI in stable COPD outpatients, as compared with a healthy control group, to quantify its relationship with several important clinical features in COPD, and to study its potential usefulness to predict COPD exacerbations and hospital admissions. Methods: The SI was calculated in 18 healthy control subjects and 65 stable COPD outpatients were included in the study. Patients were prospectively followed for 1 year after being enrolled in the study. Results: COPD patients had a lower SI than controls, that is lower muscle mass. Furthermore, patients with a modified Medical Research Council dyspnea score ≥2, patients with a COPD Assessment Test score ≥10, and patients with a high risk of exacerbation had lower levels of SI compared with patients without these characteristics. SI correlated with FEV1 (r = 0.491, p < 0.001), the 6-min walking test (r = 0.560, p = 0.001), and the Fat-Free Mass Index (r = 0.431, p = 0.017). Univariate and multivariate Cox proportional risk analysis showed that a low SI is an independent predictor of hospital admission in COPD outpatients followed for 1 year (HR 5.16, p = 0.025). Conclusions: The ratio serum creatinine/serum cystatin C correlates with several COPD characteristics, and it can be used to predict COPD hospitalization.

1.
Buckinx
F
,
Landi
F
,
Cesari
M
,
Fielding
RA
,
Visser
M
,
Engelke
K
, et al.
Pitfalls in the measurement of muscle mass: a need for a reference standard
.
J Cachexia Sarcopenia Muscle
.
2018
Apr
;
9
(
2
):
269
78
.
[PubMed]
2190-5991
2.
Engelen
MP
,
Schols
AM
,
Heidendal
GA
,
Wouters
EF
.
Dual-energy X-ray absorptiometry in the clinical evaluation of body composition and bone mineral density in patients with chronic obstructive pulmonary disease
.
Am J Clin Nutr
.
1998
Dec
;
68
(
6
):
1298
303
.
[PubMed]
0002-9165
3.
Lukaski
HC
,
Johnson
PE
,
Bolonchuk
WW
,
Lykken
GI
.
Assessment of fat-free mass using bioelectrical impedance measurements of the human body
.
Am J Clin Nutr
.
1985
Apr
;
41
(
4
):
810
7
.
[PubMed]
0002-9165
4.
Creutzberg
EC
,
Schols
AM
,
Bothmer-Quaedvlieg
FC
,
Wouters
EF
.
Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function
.
Eur J Clin Nutr
.
1998
Jun
;
52
(
6
):
396
401
.
[PubMed]
0954-3007
5.
Vilaró
J
,
Ramirez-Sarmiento
A
,
Martínez-Llorens
JM
,
Mendoza
T
,
Alvarez
M
,
Sánchez-Cayado
N
, et al.
Global muscle dysfunction as a risk factor of readmission to hospital due to COPD exacerbations
.
Respir Med
.
2010
Dec
;
104
(
12
):
1896
902
.
[PubMed]
0954-6111
6.
Schols
AM
,
Broekhuizen
R
,
Weling-Scheepers
CA
,
Wouters
EF
.
Body composition and mortality in chronic obstructive pulmonary disease
.
Am J Clin Nutr
.
2005
Jul
;
82
(
1
):
53
9
.
[PubMed]
0002-9165
7.
van de Bool
C
,
Rutten
EP
,
Franssen
FM
,
Wouters
EF
,
Schols
AM
.
Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD
.
Eur Respir J
.
2015
Aug
;
46
(
2
):
336
45
.
[PubMed]
0903-1936
8.
Shoup
R
,
Dalsky
G
,
Warner
S
,
Davies
M
,
Connors
M
,
Khan
M
, et al.
Body composition and health-related quality of life in patients with obstructive airways disease
.
Eur Respir J
.
1997
Jul
;
10
(
7
):
1576
80
.
[PubMed]
0903-1936
9.
Ischaki
E
,
Papatheodorou
G
,
Gaki
E
,
Papa
I
,
Koulouris
N
,
Loukides
S
.
Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity
.
Chest
.
2007
Jul
;
132
(
1
):
164
9
.
[PubMed]
0012-3692
10.
Cockcroft
DW
,
Gault
MH
.
Prediction of creatinine clearance from serum creatinine
.
Nephron
.
1976
;
16
(
1
):
31
41
.
[PubMed]
0028-2766
11.
Levey
AS
,
Bosch
JP
,
Lewis
JB
,
Greene
T
,
Rogers
N
,
Roth
D
;
Modification of Diet in Renal Disease Study Group
.
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation
.
Ann Intern Med
.
1999
Mar
;
130
(
6
):
461
70
.
[PubMed]
0003-4819
12.
Heymsfield
SB
,
Arteaga
C
,
McManus
C
,
Smith
J
,
Moffitt
S
.
Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method
.
Am J Clin Nutr
.
1983
Mar
;
37
(
3
):
478
94
.
[PubMed]
0002-9165
13.
Goldberg
TH
,
Finkelstein
MS
.
Difficulties in estimating glomerular filtration rate in the elderly
.
Arch Intern Med
.
1987
Aug
;
147
(
8
):
1430
3
.
[PubMed]
0003-9926
14.
Abrahamson
M
,
Olafsson
I
,
Palsdottir
A
,
Ulvsbäck
M
,
Lundwall
A
,
Jensson
O
, et al.
Structure and expression of the human cystatin C gene
.
Biochem J
.
1990
Jun
;
268
(
2
):
287
94
.
[PubMed]
0264-6021
15.
Kyhse-Andersen
J
,
Schmidt
C
,
Nordin
G
,
Andersson
B
,
Nilsson-Ehle
P
,
Lindström
V
, et al.
Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate
.
Clin Chem
.
1994
Oct
;
40
(
10
):
1921
6
.
[PubMed]
0009-9147
16.
Jung
K
,
Jung
M
.
Cystatin C: a promising marker of glomerular filtration rate to replace creatinine
.
Nephron
.
1995
;
70
(
3
):
370
1
.
[PubMed]
0028-2766
17.
Kashani
KB
,
Frazee
EN
,
Kukrálová
L
,
Sarvottam
K
,
Herasevich
V
,
Young
PM
, et al.
Evaluating Muscle Mass by Using Markers of Kidney Function: Development of the Sarcopenia Index
.
Crit Care Med
.
2017
Jan
;
45
(
1
):
e23
9
.
[PubMed]
0090-3493
18.
Kashani
K
,
Sarvottam
K
,
Pereira
NL
,
Barreto
EF
,
Kennedy
CC
.
The sarcopenia index: A novel measure of muscle mass in lung transplant candidates
.
Clin Transplant
.
2018
Mar
;
32
(
3
):
e13182
.
[PubMed]
0902-0063
19.
Vogelmeier
CF
,
Criner
GJ
,
Martinez
FJ
,
Anzueto
A
,
Barnes
PJ
,
Bourbeau
J
, et al.
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
.
Am J Respir Crit Care Med
.
2017
Mar
;
195
(
5
):
557
82
.
[PubMed]
1073-449X
20.
Schilling
RS
,
Hughes
JP
,
Dingwall-Fordyce
I
.
Disagreement between observers in an epidemiological study of respiratory disease
.
BMJ
.
1955
Jan
;
1
(
4905
):
65
8
.
[PubMed]
0007-1447
21.
Celli
BR
,
MacNee
W
,
Agusti
A
,
Anzueto
A
,
Berg
B
,
Buist
AS
, et al.;
ATS/ERS Task Force
.
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
.
Eur Respir J
.
2004
Jun
;
23
(
6
):
932
46
.
[PubMed]
0903-1936
22.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories
.
ATS statement: guidelines for the six-minute walk test
.
Am J Respir Crit Care Med
.
2002
Jul
;
166
(
1
):
111
7
.
[PubMed]
1073-449X
23.
Tetsuka
S
,
Morita
M
,
Ikeguchi
K
,
Nakano
I
.
Creatinine/cystatin C ratio as a surrogate marker of residual muscle mass in amyotrophic lateral sclerosis
.
Neurol Clin Neurosci
.
2013
;
1
(
1
):
32
7
. 2049-4173
24.
Kim
SW
,
Jung
HW
,
Kim
CH
,
Kim
KI
,
Chin
HJ
,
Lee
H
.
A new equation to estimate muscle mass from creatinine and cystatin C
.
PLoS One
.
2016
Feb
;
11
(
2
):
e0148495
.
[PubMed]
1932-6203
25.
-
Osaka
T
,
Hamaguchi
M
,
Hashimoto
Y
,
Ushigome
E
,
Tanaka
M
,
Yamazaki
M
,
Fukui
M
:
Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes.
Diabetes Res Clin Pract.
2018
;pii: S0168-8227;31946-0.
26.
Munhoz da Rocha Lemos Costa
T
,
Costa
FM
,
Jonasson
TH
,
Moreira
CA
,
Boguszewski
CL
,
Borba
VZ
.
Body composition and sarcopenia in patients with chronic obstructive pulmonary disease
.
Endocrine
.
2018
Apr
;
60
(
1
):
95
102
.
[PubMed]
1355-008X
27.
Koo
HK
,
Park
JH
,
Park
HK
,
Jung
H
,
Lee
SS
.
Conflicting role of sarcopenia and obesity in male patients with chronic obstructive pulmonary disease: Korean National Health and Nutrition Examination Survey
.
PLoS One
.
2014
Oct
;
9
(
10
):
e110448
.
[PubMed]
1932-6203
28.
Jones
SE
,
Maddocks
M
,
Kon
SS
,
Canavan
JL
,
Nolan
CM
,
Clark
AL
, et al.
Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation
.
Thorax
.
2015
Mar
;
70
(
3
):
213
8
.
[PubMed]
0040-6376
29.
Husebø
GR
,
Bakke
PS
,
Aanerud
M
,
Hardie
JA
,
Ueland
T
,
Grønseth
R
, et al.
Predictors of exacerbations in chronic obstructive pulmonary disease—results from the Bergen COPD cohort study
.
PLoS One
.
2014
Oct
;
9
(
10
):
e109721
.
[PubMed]
1932-6203
30.
Faganello
MM
,
Tanni
SE
,
Sanchez
FF
,
Pelegrino
NR
,
Lucheta
PA
,
Godoy
I
.
BODE index and GOLD staging as predictors of 1-year exacerbation risk in chronic obstructive pulmonary disease
.
Am J Med Sci
.
2010
Jan
;
339
(
1
):
10
4
.
[PubMed]
0002-9629
31.
Motegi
T
,
Jones
RC
,
Ishii
T
,
Hattori
K
,
Kusunoki
Y
,
Furutate
R
, et al.
A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations
.
Int J Chron Obstruct Pulmon Dis
.
2013
;
8
:
259
71
.
[PubMed]
1176-9106
32.
Luo
Y
,
Zhou
L
,
Li
Y
,
Guo
S
,
Li
X
,
Zheng
J
, et al.
Fat-Free Mass Index for Evaluating the Nutritional Status and Disease Severity in COPD
.
Respir Care
.
2016
May
;
61
(
5
):
680
8
.
[PubMed]
0020-1324
33.
Kyle
UG
,
Schutz
Y
,
Dupertuis
YM
,
Pichard
C
.
Body composition interpretation. Contributions of the fat-free mass index and the body fat mass index
.
Nutrition
.
2003
Jul-Aug
;
19
(
7-8
):
597
604
.
[PubMed]
0899-9007
34.
Celli
BR
,
Cote
CG
,
Marin
JM
,
Casanova
C
,
Montes de Oca
M
,
Mendez
RA
, et al.
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease
.
N Engl J Med
.
2004
Mar
;
350
(
10
):
1005
12
.
[PubMed]
0028-4793
35.
Vermeeren
MA
,
Schols
AM
,
Wouters
EF
.
Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD
.
Eur Respir J
.
1997
Oct
;
10
(
10
):
2264
9
.
[PubMed]
0903-1936
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.